

Regd. Office :

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com

Date : March 30, 2013

Bombay Stock Exchange Limited
1st Floor, P.J. Towers
Dalal Street
MUMBAI - 400 001

Attention: Mr. Sanjay Golecha
Mr. Gopalkrishnan

Fax No. 022 - 22722039 / 3121

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra-Kurla Complex
Bandra - (East)
Mumbai - 400 051

Attention: Famroze Pochara
Asst. Vice President

Fax No. 022 - 26598237/38

Ahmedabad Stock Exchange Limited
Kamdheni Complex
Opp. Sahajanand College
Panjara Pole,
Ahmedabad - 380 015

Fax No. 079 - 26308877

Reg. : Press Release

Dear Sir / Madam


We are pleased to inform that the Company has received tentative approval for Amlodipine Besylate and Benazepril Hydrochloride Capsules from the USFDA in the different strengths. It falls in anti-hypertensive segment.

Please find attached herewith Press Release, which gives more details and is self explanatory.

Please bring the information to the notice of the members of the Exchange and the investors at large.

Thanking you,

Yours faithfully,
FOR CADILA HEALTHCARE LIMITED



UPEN H. SHAH
COMPANY SECRETARY

Encl. As above.

Zydus Cadila receives tentative approval for Amlodipine Besylate and Benazepril Hydrochloride Capsules

Ahmedabad, 30 March 2013

Zydus Cadila has received tentative approval from the USFDA for Amlodipine Besylate and Benazepril Hydrochloride Capsules, in the strengths of 2.5 mg/10 mg, 5 mg/10 mg, 5 mg/20 mg and 10 mg/20 mg. It falls in the anti-hypertensive segment.

The estimated sales in 2012 as per IMS for Amlodipine Besylate and Benazepril Hydrochloride Capsules, was USD 384.8 million.

The group now has 78 approvals and has so far filed 173 ANDAs since the commencement of the filing process in FY 2003-04.
